Agree, if each of the NEW leads have blockbuster potential and the pace of PYC’s platform/team is to produce 2-3 pre-clinical block buster leads a year, then PYC market is only now hostage what probability mr market ascribes to each lead, for simplicIty sake (NPV figures would just make us ridiculously undervalued) currently we’re valued at 23% chance of achieve if VP-001 first year revenues - you get other year’s revenues/other lead potential are for FREE:
VP-001 = US $1-2 B annuity a year VP-002 = US $1 B annuity a year
PYC-001 = $US $5+B annuity a year
figures above are from PYC Feb21 corporate presentation.
CNS-001 ?? Dark horse … see the extract for next week’s conference…
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)